![Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Respiratory Medicine Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/53b7553a-3c70-4bc4-8d4b-fb53f9074605/gr1.gif)
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Respiratory Medicine
![Bias and coverage of independence estimators in simulation study 1. PE... | Download Scientific Diagram Bias and coverage of independence estimators in simulation study 1. PE... | Download Scientific Diagram](https://www.researchgate.net/publication/355785821/figure/fig1/AS:1084772688367616@1635641371655/Bias-and-coverage-of-independence-estimators-in-simulation-study-1-PE-per-episode-PP.png)
Bias and coverage of independence estimators in simulation study 1. PE... | Download Scientific Diagram
![Bias in estimators across different treatment effect and non-enrolment... | Download Scientific Diagram Bias in estimators across different treatment effect and non-enrolment... | Download Scientific Diagram](https://www.researchgate.net/publication/355785821/figure/fig2/AS:1084772688367617@1635641371671/Bias-in-estimators-across-different-treatment-effect-and-non-enrolment-scenarios-for.png)
Bias in estimators across different treatment effect and non-enrolment... | Download Scientific Diagram
![Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) | Leukemia Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-0718-z/MediaObjects/41375_2020_718_Fig1_HTML.png)
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) | Leukemia
![Average Daily Census and Hours per Patient Day in Study Units During... | Download Scientific Diagram Average Daily Census and Hours per Patient Day in Study Units During... | Download Scientific Diagram](https://www.researchgate.net/publication/269348288/figure/tbl1/AS:964996863365122@1607084589396/Average-Daily-Census-and-Hours-per-Patient-Day-in-Study-Units-During-the-One-Hour-and.png)
Average Daily Census and Hours per Patient Day in Study Units During... | Download Scientific Diagram
![The Effect of Medication Reconciliation via a Patient Portal on Medication Discrepancies: A Randomized Noninferiority Study - Journal of the American Medical Directors Association The Effect of Medication Reconciliation via a Patient Portal on Medication Discrepancies: A Randomized Noninferiority Study - Journal of the American Medical Directors Association](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/05b968f7-b505-4b4b-842f-e633ed94d798/gr1_lrg.jpg)
The Effect of Medication Reconciliation via a Patient Portal on Medication Discrepancies: A Randomized Noninferiority Study - Journal of the American Medical Directors Association
![Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing - National Academy of Medicine Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing - National Academy of Medicine](https://nam.edu/wp-content/uploads/2019/06/Box-4.png)
Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing - National Academy of Medicine
![Clinical Trial Protocol for PSMA-SELECT: A Dutch National Randomised Study of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as a Triage Tool for Pelvic Lymph Node Dissection in Patients Undergoing Radical ... Clinical Trial Protocol for PSMA-SELECT: A Dutch National Randomised Study of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as a Triage Tool for Pelvic Lymph Node Dissection in Patients Undergoing Radical ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/ac118ecd-bd71-4675-bf6f-1fb338d0b2bb/gr1.jpg)
Clinical Trial Protocol for PSMA-SELECT: A Dutch National Randomised Study of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as a Triage Tool for Pelvic Lymph Node Dissection in Patients Undergoing Radical ...
![Outpatient process and study events per patient. Patients from a larger... | Download Scientific Diagram Outpatient process and study events per patient. Patients from a larger... | Download Scientific Diagram](https://www.researchgate.net/publication/5226504/figure/fig1/AS:601700012408856@1520467870901/Outpatient-process-and-study-events-per-patient-Patients-from-a-larger-study-on-patient.png)
Outpatient process and study events per patient. Patients from a larger... | Download Scientific Diagram
![At a Cost of $10,405 Per Patient Stay, Hypoglycemia in The Hospital Cannot Be Ignored | Business Wire At a Cost of $10,405 Per Patient Stay, Hypoglycemia in The Hospital Cannot Be Ignored | Business Wire](https://mms.businesswire.com/media/20190115005280/en/700578/5/Hypoglycemia_Case_Study.jpg)
At a Cost of $10,405 Per Patient Stay, Hypoglycemia in The Hospital Cannot Be Ignored | Business Wire
![Virta Health's Diabetes Reversal Treatment Drives Savings of More Than $10k Per Patient Over Two Years, New Analysis Shows | Business Wire Virta Health's Diabetes Reversal Treatment Drives Savings of More Than $10k Per Patient Over Two Years, New Analysis Shows | Business Wire](https://mms.businesswire.com/media/20210915005825/en/906595/5/PMPM_Costs_Over_Time.jpg)
Virta Health's Diabetes Reversal Treatment Drives Savings of More Than $10k Per Patient Over Two Years, New Analysis Shows | Business Wire
![Qliance study shows monthly-fee primary care model saves 20 percent on claims - State of Reform | State of Reform Qliance study shows monthly-fee primary care model saves 20 percent on claims - State of Reform | State of Reform](https://stateofreform.com/wp-content/uploads/2015/01/Qliance-data.jpg)
Qliance study shows monthly-fee primary care model saves 20 percent on claims - State of Reform | State of Reform
![Independence estimators for re-randomisation trials in multi-episode settings: a simulation study | BMC Medical Research Methodology | Full Text Independence estimators for re-randomisation trials in multi-episode settings: a simulation study | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-021-01433-4/MediaObjects/12874_2021_1433_Fig2_HTML.png)
Independence estimators for re-randomisation trials in multi-episode settings: a simulation study | BMC Medical Research Methodology | Full Text
![Identification of preoperative predictors for acute postsurgical pain and for pain at three months after surgery: a prospective observational study | Scientific Reports Identification of preoperative predictors for acute postsurgical pain and for pain at three months after surgery: a prospective observational study | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-95963-y/MediaObjects/41598_2021_95963_Fig1_HTML.png)